Giant Cell Hepatitis With Autoimmune Hemolytic Anemia

Autoimmune Disease MONDO:1060166 Pathograph 13 Autoimmune hepatitis Autoimmune hemolytic anemia

Giant cell hepatitis with autoimmune hemolytic anemia is a rare autoimmune disease of infancy and early childhood in which severe liver disease with giant-cell transformation of hepatocytes occurs together with Coombs-positive autoimmune hemolytic anemia. This entry is scoped to the combined hepatic and hematologic syndrome rather than isolated autoimmune hemolytic anemia.

Ask OpenScientist

Ask a research question about Giant Cell Hepatitis With Autoimmune Hemolytic Anemia. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

4
Pathophys.
2
Histopath.
8
Phenotypes
13
Pathograph
5
Treatments
10
References
1
Deep Research
⚙

Pathophysiology

4
Systemic B-cell autoimmunity
The syndrome is best supported as a systemic humoral autoimmune disorder: Coombs-positive hemolysis distinguishes it from early-onset autoimmune hepatitis, and liver injury responds in many refractory cases to B-cell depletion.
B cell link
immunoglobulin mediated immune response link ⚠ ABNORMAL
Downstream
Complement-mediated hepatocyte injury B-cell autoimmunity can drive antibody and complement injury in the liver.
Coombs-positive erythrocyte destruction Humoral autoimmunity also produces Coombs-positive hemolytic anemia.
Show evidence (1 reference)
PMID:23969541 SUPPORT Human Clinical
"Widespread complement-mediated hepatocyte injury and typical C3a and C5a complement-driven liver inflammation along with Coombs-positive hemolytic anemia in GCH-AHA provide convincing evidence that systemic B-cell autoimmunity plays a central pathologic mechanism in the disease."
This mechanistic case series directly identifies systemic B-cell autoimmunity as central to GCH-AHA.
Complement-mediated hepatocyte injury
Complement activation injures hepatocytes across the lobule, with C5b-9 membrane attack complex deposition and an inflammatory pattern enriched for macrophages and neutrophils rather than classic portal autoimmune hepatitis.
hepatocyte link macrophage link neutrophil link
complement activation link ↑ INCREASED
liver link
Downstream
Giant cell transformation of hepatocytes Complement-associated hepatocyte injury contributes to giant-cell transformation on biopsy.
Elevated hepatic transaminases Hepatocyte injury is reflected by elevated circulating aminotransferase activity.
Show evidence (2 references)
PMID:23969541 SUPPORT Human Clinical
"C5b-9 staining showed high-grade complement-mediated pan-lobular hepatocyte injury in all of the cases with GCH-AHA, whereas little C5b-9 was seen in hepatocytes in cases with AIH."
The abstract directly supports pan-lobular complement-mediated hepatocyte injury in GCH-AHA.
PMID:23969541 SUPPORT Human Clinical
"Inflammation in GCH-AHA comprised mainly lobular macrophages and neutrophils, whereas portal and periportal T-cell and B-cell inflammation characterized cases with AIH."
This supports the lobular macrophage/neutrophil inflammatory pattern and distinction from classic autoimmune hepatitis.
Giant cell transformation of hepatocytes
Liver biopsy shows diffuse giant-cell transformation of hepatocytes, often with architectural damage and fibrosis in severe or recurrent disease.
hepatocyte link
liver link
Downstream
Hepatic failure Progressive hepatocellular damage can lead to liver failure in severe cases.
Show evidence (1 reference)
PMID:8159622 SUPPORT Human Clinical
"Histologically, the livers showed loss of lobular architecture with diffuse giant cell transformation of hepatocytes and portal and pericellular fibrosis."
This classic pathology report directly supports the defining hepatic histopathology.
Coombs-positive erythrocyte destruction
Autoimmune hemolysis targets red blood cells, producing anemia that may precede the hepatitis by weeks to months and can relapse independently of liver inflammation.
erythrocyte link
humoral immune response link ⚠ ABNORMAL
Downstream
Autoimmune hemolytic anemia Immune-mediated red-cell destruction manifests as autoimmune hemolytic anemia.
Show evidence (1 reference)
PMID:32206631 SUPPORT Human Clinical
"Giant cell hepatitis with autoimmune hemolytic anemia (AHA) is a rare disease of infancy characterized by the presence of both Coombs-positive hemolytic anemia and progressive liver disease with giant cell transformation of hepatocytes."
This case report abstract directly supports the combined Coombs-positive hemolysis and progressive liver disease phenotype.
✶

Histopathology

2
Diffuse giant cell transformation of hepatocytes
Biopsy shows diffuse multinucleated giant-cell transformation of hepatocytes, with fibrosis reported in classic cases.
Show evidence (1 reference)
PMID:8159622 SUPPORT Human Clinical
"Histologically, the livers showed loss of lobular architecture with diffuse giant cell transformation of hepatocytes and portal and pericellular fibrosis."
This directly supports the defining histopathologic finding.
Pan-lobular C5b-9 hepatocyte deposition
C5b-9 complement complex staining across hepatocytes supports complement mediated liver injury and helps distinguish GCH-AIHA from classic autoimmune hepatitis in the mechanistic series.
Show evidence (1 reference)
PMID:23969541 SUPPORT Human Clinical
"C5b-9 staining showed high-grade complement-mediated pan-lobular hepatocyte injury in all of the cases with GCH-AHA, whereas little C5b-9 was seen in hepatocytes in cases with AIH."
This supports complement immunostaining as a mechanistic histopathology feature.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Giant Cell Hepatitis With Autoimmune Hemolytic Anemia Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

8
Blood 1
Autoimmune hemolytic anemia Autoimmune hemolytic anemia (HP:0001890)
Show evidence (1 reference)
PMID:25201797 SUPPORT Human Clinical
"Giant cell hepatitis with autoimmune hemolytic anemia (GCH-AHA) is a rare autoimmune disease of infancy characterized by severe liver disease associated with Coombs-positive hemolytic anemia."
The abstract directly supports Coombs-positive hemolytic anemia as part of the defining syndrome.
Cardiovascular 1
Splenomegaly Splenomegaly (HP:0001744)
Show evidence (1 reference)
PMID:24792633 SUPPORT Human Clinical
"The median age of the children was 7 months (2-12 months), follow-up lasted 44 months (12-78 months), median (min-max), and the main observed symptoms were jaundice and hepatosplenomegaly."
This supports splenomegaly as part of hepatosplenomegaly in pediatric GCH-AIHA.
Digestive 3
Jaundice Jaundice (HP:0000952)
Show evidence (1 reference)
PMID:21349541 SUPPORT Human Clinical
"Children (nine boys; median age, 6 months) presented with jaundice, hepatomegaly, elevated aminotransferases, a positive Coombs test, and diffuse giant-cell transformation of hepatocytes on histology."
This cohort abstract lists jaundice among presenting features.
Hepatomegaly Hepatomegaly (HP:0002240)
Show evidence (1 reference)
PMID:24792633 SUPPORT Human Clinical
"The median age of the children was 7 months (2-12 months), follow-up lasted 44 months (12-78 months), median (min-max), and the main observed symptoms were jaundice and hepatosplenomegaly."
This severe-case series identifies hepatosplenomegaly, including hepatomegaly, as a main observed symptom.
Hepatic failure Hepatic failure (HP:0001399)
Show evidence (1 reference)
PMID:24792633 SUPPORT Human Clinical
"The disease is aggressive and may lead to liver or multiorgan failure with fatal prognosis."
This abstract directly supports liver failure as a severe manifestation.
Integument 1
Pallor Pallor (HP:0000980)
Show evidence (1 reference)
PMID:32206631 SUPPORT Human Clinical
"The clinical features included jaundice, pallor, and red urine."
This case report abstract directly documents pallor among clinical features of GCH-AIHA.
Metabolism 1
Elevated hepatic transaminases Elevated circulating hepatic transaminase concentration (HP:0002910)
Show evidence (1 reference)
PMID:21349541 SUPPORT Human Clinical
"Children (nine boys; median age, 6 months) presented with jaundice, hepatomegaly, elevated aminotransferases, a positive Coombs test, and diffuse giant-cell transformation of hepatocytes on histology."
This cohort abstract directly documents elevated aminotransferases.
Other 1
Giant cell hepatitis Giant cell hepatitis (HP:0200084)
Show evidence (1 reference)
PMID:21349541 SUPPORT Human Clinical
"Children (nine boys; median age, 6 months) presented with jaundice, hepatomegaly, elevated aminotransferases, a positive Coombs test, and diffuse giant-cell transformation of hepatocytes on histology."
This cohort abstract directly documents diffuse giant-cell transformation of hepatocytes.
💊

Treatments

5
Prednisone and azathioprine immunosuppression
Action: Pharmacotherapy NCIT:C15986
Agent: prednisone ↗ azathioprine ↗
Prednisone with azathioprine has been used as traditional immunosuppression; it can induce remission, but relapses and prolonged treatment are common.
Target Phenotypes: Giant cell hepatitis ↗ Autoimmune hemolytic anemia ↗
Show evidence (2 references)
PMID:21349541 SUPPORT Human Clinical
"Treatment with prednisone and azathioprine, plus, in three children, cyclosporine, resulted in complete remission in eight, partial remission in six, and failure in two."
This cohort supports prednisone/azathioprine-based immunosuppression as a remission-inducing treatment with incomplete response.
PMID:21349541 SUPPORT Human Clinical
"Relapses of hepatitis and/or anemia occurred in 11 and 10 children, respectively, requiring prolonged high levels of immunosuppression, and splenectomy or Rituximab, respectively."
This supports the relapsing course and frequent need for prolonged or escalated treatment.
Rituximab
Action: Pharmacotherapy NCIT:C15986
Agent: rituximab ↗
Rituximab is an anti-CD20 monoclonal antibody that targets B lymphocytes and is supported by disease-specific series for refractory or severe disease.
Mechanism Target:
INHIBITS Systemic B-cell autoimmunity — Rituximab depletes CD20-positive B cells implicated in systemic humoral autoimmunity.
INHIBITS Complement-mediated hepatocyte injury — B-cell depletion is expected to reduce upstream antibody-driven complement injury.
Show evidence (2 references)
PMID:25201797 SUPPORT Human Clinical
"We describe here the detailed clinical evolution of 4 children with GCH-AHA who showed a complete response to rituximab."
This case series directly supports rituximab response in GCH-AHA.
PMID:23969541 SUPPORT Human Clinical
"Our findings support B-cell-directed immunotherapy as a first-line treatment of GCH-AHA."
The mechanistic study links complement/B-cell pathology to B-cell-directed treatment.
Intravenous immunoglobulin
Action: Intravenous Immunoglobulin Therapy NCIT:C121331
Agent: Therapeutic Immune Globulin ↗
IVIG can reduce liver enzyme activity and help maintain remission as an adjunct, but repeated infusions have temporary efficacy and are not routine long-term therapy.
Target Phenotypes: Elevated circulating hepatic transaminase concentration ↗
Show evidence (2 references)
PMID:26138133 SUPPORT Human Clinical
"IVIg infusions as first-line therapy associated with prednisone and other immunosuppressive drugs significantly (P=0.04) reduced the aminotransferase activity in all patients and normalized prothrombin activity in the only patient with severe liver dysfunction."
This multicenter series supports IVIG-associated improvement in liver biochemical activity.
PMID:26138133 PARTIAL Human Clinical
"Repeated IVIg infusions may help maintain remission, however, due to their temporary efficacy, they should not be routinely employed."
This supports IVIG as useful but temporary adjunctive therapy rather than routine maintenance.
Liver transplantation
Action: organ transplantation MAXO:0010039
Liver transplantation has been used for advanced liver disease, but the syndrome is primarily managed by immune control when possible.
Target Phenotypes: Hepatic failure ↗
Show evidence (1 reference)
PMID:21349541 PARTIAL Human Clinical
"One child is alive 9 years after liver transplantation."
This supports liver transplantation as a possible survival-associated intervention in selected severe cases, but not as routine first-line therapy.
Splenectomy
Action: splenectomy MAXO:0001077
Splenectomy has been used as an escalation option for relapsing or refractory hemolytic anemia in the long-term cohort.
Target Phenotypes: Autoimmune hemolytic anemia ↗
Show evidence (1 reference)
PMID:21349541 SUPPORT Human Clinical
"Relapses of hepatitis and/or anemia occurred in 11 and 10 children, respectively, requiring prolonged high levels of immunosuppression, and splenectomy or Rituximab, respectively."
This cohort abstract names splenectomy as an escalation treatment used for relapsing anemia.
{ }

Source YAML

click to show 
name: Giant Cell Hepatitis With Autoimmune Hemolytic Anemia
creation_date: '2026-05-07T02:03:20Z'
updated_date: '2026-05-07T02:18:30Z'
description: >-
  Giant cell hepatitis with autoimmune hemolytic anemia is a rare autoimmune
  disease of infancy and early childhood in which severe liver disease with
  giant-cell transformation of hepatocytes occurs together with Coombs-positive
  autoimmune hemolytic anemia. This entry is scoped to the combined hepatic and
  hematologic syndrome rather than isolated autoimmune hemolytic anemia.
category: Autoimmune Disease
disease_term:
  preferred_term: giant cell hepatitis with autoimmune hemolytic anemia
  term:
    id: MONDO:1060166
    label: giant cell hepatitis with autoimmune hemolytic anemia
parents:
- Autoimmune hepatitis
- Autoimmune hemolytic anemia
synonyms:
- GCH-AHA
- GCH-AIHA
- Giant cell hepatitis associated with autoimmune hemolytic anemia
pathophysiology:
- name: Systemic B-cell autoimmunity
  description: >-
    The syndrome is best supported as a systemic humoral autoimmune disorder:
    Coombs-positive hemolysis distinguishes it from early-onset autoimmune
    hepatitis, and liver injury responds in many refractory cases to B-cell
    depletion.
  downstream:
  - target: Complement-mediated hepatocyte injury
    description: B-cell autoimmunity can drive antibody and complement injury in the liver.
  - target: Coombs-positive erythrocyte destruction
    description: Humoral autoimmunity also produces Coombs-positive hemolytic anemia.
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  biological_processes:
  - preferred_term: immunoglobulin mediated immune response
    modifier: ABNORMAL
    term:
      id: GO:0016064
      label: immunoglobulin mediated immune response
  evidence:
  - reference: PMID:23969541
    reference_title: "Humoral immune mechanism of liver injury in giant cell hepatitis with autoimmune hemolytic anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Widespread complement-mediated hepatocyte injury and typical C3a and C5a
      complement-driven liver inflammation along with Coombs-positive hemolytic
      anemia in GCH-AHA provide convincing evidence that systemic B-cell
      autoimmunity plays a central pathologic mechanism in the disease.
    explanation: This mechanistic case series directly identifies systemic B-cell autoimmunity as central to GCH-AHA.
- name: Complement-mediated hepatocyte injury
  description: >-
    Complement activation injures hepatocytes across the lobule, with C5b-9
    membrane attack complex deposition and an inflammatory pattern enriched for
    macrophages and neutrophils rather than classic portal autoimmune hepatitis.
  downstream:
  - target: Giant cell transformation of hepatocytes
    description: Complement-associated hepatocyte injury contributes to giant-cell transformation on biopsy.
  - target: Elevated hepatic transaminases
    description: Hepatocyte injury is reflected by elevated circulating aminotransferase activity.
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  - preferred_term: neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  biological_processes:
  - preferred_term: complement activation
    modifier: INCREASED
    term:
      id: GO:0006956
      label: complement activation
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  evidence:
  - reference: PMID:23969541
    reference_title: "Humoral immune mechanism of liver injury in giant cell hepatitis with autoimmune hemolytic anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      C5b-9 staining showed high-grade complement-mediated pan-lobular hepatocyte
      injury in all of the cases with GCH-AHA, whereas little C5b-9 was seen in
      hepatocytes in cases with AIH.
    explanation: The abstract directly supports pan-lobular complement-mediated hepatocyte injury in GCH-AHA.
  - reference: PMID:23969541
    reference_title: "Humoral immune mechanism of liver injury in giant cell hepatitis with autoimmune hemolytic anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Inflammation in GCH-AHA comprised mainly lobular macrophages and neutrophils,
      whereas portal and periportal T-cell and B-cell inflammation characterized
      cases with AIH.
    explanation: This supports the lobular macrophage/neutrophil inflammatory pattern and distinction from classic autoimmune hepatitis.
- name: Giant cell transformation of hepatocytes
  description: >-
    Liver biopsy shows diffuse giant-cell transformation of hepatocytes, often
    with architectural damage and fibrosis in severe or recurrent disease.
  downstream:
  - target: Hepatic failure
    description: Progressive hepatocellular damage can lead to liver failure in severe cases.
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  evidence:
  - reference: PMID:8159622
    reference_title: "Coombs-positive autoimmune hemolytic anemia and postinfantile giant cell hepatitis in children."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Histologically, the livers showed loss of lobular architecture with diffuse
      giant cell transformation of hepatocytes and portal and pericellular fibrosis.
    explanation: This classic pathology report directly supports the defining hepatic histopathology.
- name: Coombs-positive erythrocyte destruction
  description: >-
    Autoimmune hemolysis targets red blood cells, producing anemia that may
    precede the hepatitis by weeks to months and can relapse independently of
    liver inflammation.
  downstream:
  - target: Autoimmune hemolytic anemia
    description: Immune-mediated red-cell destruction manifests as autoimmune hemolytic anemia.
  cell_types:
  - preferred_term: erythrocyte
    term:
      id: CL:0000232
      label: erythrocyte
  biological_processes:
  - preferred_term: humoral immune response
    modifier: ABNORMAL
    term:
      id: GO:0006959
      label: humoral immune response
  evidence:
  - reference: PMID:32206631
    reference_title: "Successful Treatment of a Korean Infant with Giant Cell Hepatitis with Autoimmune Hemolytic Anemia Using Rituximab."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Giant cell hepatitis with autoimmune hemolytic anemia (AHA) is a rare disease
      of infancy characterized by the presence of both Coombs-positive hemolytic
      anemia and progressive liver disease with giant cell transformation of
      hepatocytes.
    explanation: This case report abstract directly supports the combined Coombs-positive hemolysis and progressive liver disease phenotype.
phenotypes:
- category: Gastrointestinal
  name: Giant cell hepatitis
  description: >-
    Giant cell hepatitis on liver biopsy is the defining hepatic manifestation
    of this syndrome.
  phenotype_term:
    preferred_term: Giant cell hepatitis
    term:
      id: HP:0200084
      label: Giant cell hepatitis
  evidence:
  - reference: PMID:21349541
    reference_title: "Giant cell hepatitis with autoimmune hemolytic anemia in early childhood: long-term outcome in 16 children."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Children (nine boys; median age, 6 months) presented with jaundice,
      hepatomegaly, elevated aminotransferases, a positive Coombs test, and diffuse
      giant-cell transformation of hepatocytes on histology.
    explanation: This cohort abstract directly documents diffuse giant-cell transformation of hepatocytes.
- category: Hematologic
  name: Autoimmune hemolytic anemia
  description: >-
    Coombs-positive autoimmune hemolytic anemia occurs with the liver disease
    and may be the first clinical manifestation.
  phenotype_term:
    preferred_term: Autoimmune hemolytic anemia
    term:
      id: HP:0001890
      label: Autoimmune hemolytic anemia
  evidence:
  - reference: PMID:25201797
    reference_title: "Anti-CD20 treatment of giant cell hepatitis with autoimmune hemolytic anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Giant cell hepatitis with autoimmune hemolytic anemia (GCH-AHA) is a rare
      autoimmune disease of infancy characterized by severe liver disease associated
      with Coombs-positive hemolytic anemia.
    explanation: The abstract directly supports Coombs-positive hemolytic anemia as part of the defining syndrome.
- category: Hematologic
  name: Pallor
  description: Pallor can occur as a visible manifestation of the hemolytic anemia component.
  phenotype_term:
    preferred_term: Pallor
    term:
      id: HP:0000980
      label: Pallor
  evidence:
  - reference: PMID:32206631
    reference_title: "Successful Treatment of a Korean Infant with Giant Cell Hepatitis with Autoimmune Hemolytic Anemia Using Rituximab."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The clinical features included jaundice, pallor, and red urine.
    explanation: This case report abstract directly documents pallor among clinical features of GCH-AIHA.
- category: Gastrointestinal
  name: Jaundice
  description: >-
    Jaundice is a common presenting feature and can reflect both cholestatic
    hepatitis and hemolysis.
  phenotype_term:
    preferred_term: Jaundice
    term:
      id: HP:0000952
      label: Jaundice
  evidence:
  - reference: PMID:21349541
    reference_title: "Giant cell hepatitis with autoimmune hemolytic anemia in early childhood: long-term outcome in 16 children."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Children (nine boys; median age, 6 months) presented with jaundice,
      hepatomegaly, elevated aminotransferases, a positive Coombs test, and diffuse
      giant-cell transformation of hepatocytes on histology.
    explanation: This cohort abstract lists jaundice among presenting features.
- category: Gastrointestinal
  name: Hepatomegaly
  description: Liver enlargement is a recurring clinical sign in affected infants.
  phenotype_term:
    preferred_term: Hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
  evidence:
  - reference: PMID:24792633
    reference_title: "Giant cell hepatitis with autoimmune hemolytic anemia in children: proposal for therapeutic approach."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The median age of the children was 7 months (2-12 months), follow-up lasted
      44 months (12-78 months), median (min-max), and the main observed symptoms
      were jaundice and hepatosplenomegaly.
    explanation: This severe-case series identifies hepatosplenomegaly, including hepatomegaly, as a main observed symptom.
- category: Hematologic
  name: Splenomegaly
  description: Spleen enlargement can accompany hemolysis and systemic disease.
  phenotype_term:
    preferred_term: Splenomegaly
    term:
      id: HP:0001744
      label: Splenomegaly
  evidence:
  - reference: PMID:24792633
    reference_title: "Giant cell hepatitis with autoimmune hemolytic anemia in children: proposal for therapeutic approach."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The median age of the children was 7 months (2-12 months), follow-up lasted
      44 months (12-78 months), median (min-max), and the main observed symptoms
      were jaundice and hepatosplenomegaly.
    explanation: This supports splenomegaly as part of hepatosplenomegaly in pediatric GCH-AIHA.
- category: Laboratory
  name: Elevated hepatic transaminases
  description: Hepatocellular injury is reflected by elevated serum aminotransferases.
  phenotype_term:
    preferred_term: Elevated circulating hepatic transaminase concentration
    term:
      id: HP:0002910
      label: Elevated circulating hepatic transaminase concentration
  evidence:
  - reference: PMID:21349541
    reference_title: "Giant cell hepatitis with autoimmune hemolytic anemia in early childhood: long-term outcome in 16 children."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Children (nine boys; median age, 6 months) presented with jaundice,
      hepatomegaly, elevated aminotransferases, a positive Coombs test, and diffuse
      giant-cell transformation of hepatocytes on histology.
    explanation: This cohort abstract directly documents elevated aminotransferases.
- category: Gastrointestinal
  name: Hepatic failure
  description: Severe disease can progress to liver failure or multiorgan failure.
  phenotype_term:
    preferred_term: Hepatic failure
    term:
      id: HP:0001399
      label: Hepatic failure
  evidence:
  - reference: PMID:24792633
    reference_title: "Giant cell hepatitis with autoimmune hemolytic anemia in children: proposal for therapeutic approach."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The disease is aggressive and may lead to liver or multiorgan failure with
      fatal prognosis.
    explanation: This abstract directly supports liver failure as a severe manifestation.
histopathology:
- name: Diffuse giant cell transformation of hepatocytes
  description: >-
    Biopsy shows diffuse multinucleated giant-cell transformation of hepatocytes,
    with fibrosis reported in classic cases.
  diagnostic: true
  evidence:
  - reference: PMID:8159622
    reference_title: "Coombs-positive autoimmune hemolytic anemia and postinfantile giant cell hepatitis in children."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Histologically, the livers showed loss of lobular architecture with diffuse
      giant cell transformation of hepatocytes and portal and pericellular fibrosis.
    explanation: This directly supports the defining histopathologic finding.
- name: Pan-lobular C5b-9 hepatocyte deposition
  description: >-
    C5b-9 complement complex staining across hepatocytes supports complement
    mediated liver injury and helps distinguish GCH-AIHA from classic autoimmune
    hepatitis in the mechanistic series.
  diagnostic: false
  evidence:
  - reference: PMID:23969541
    reference_title: "Humoral immune mechanism of liver injury in giant cell hepatitis with autoimmune hemolytic anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      C5b-9 staining showed high-grade complement-mediated pan-lobular hepatocyte
      injury in all of the cases with GCH-AHA, whereas little C5b-9 was seen in
      hepatocytes in cases with AIH.
    explanation: This supports complement immunostaining as a mechanistic histopathology feature.
diagnosis:
- name: Liver biopsy
  diagnosis_term:
    preferred_term: biopsy of liver
    term:
      id: MAXO:0000376
      label: biopsy of liver
  description: >-
    Liver biopsy is used to document giant-cell transformation of hepatocytes and
    associated inflammation or fibrosis.
  results: Diffuse giant-cell transformation of hepatocytes supports the diagnosis.
  evidence:
  - reference: PMID:21349541
    reference_title: "Giant cell hepatitis with autoimmune hemolytic anemia in early childhood: long-term outcome in 16 children."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Children (nine boys; median age, 6 months) presented with jaundice,
      hepatomegaly, elevated aminotransferases, a positive Coombs test, and diffuse
      giant-cell transformation of hepatocytes on histology.
    explanation: This cohort abstract supports histologic confirmation as part of the diagnostic pattern.
- name: Direct Coombs test
  diagnosis_term:
    preferred_term: Coombs Test
    term:
      id: NCIT:C25163
      label: Coombs Test
  description: >-
    Direct antiglobulin testing documents Coombs-positive immune hemolysis in
    the hematologic component of the syndrome.
  results: A positive Coombs test supports autoimmune hemolytic anemia in the combined syndrome.
  evidence:
  - reference: PMID:24792633
    reference_title: "Giant cell hepatitis with autoimmune hemolytic anemia in children: proposal for therapeutic approach."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All of the children had positive direct Coombs test and biopsy-proven giant
      cell transformation of hepatocytes.
    explanation: This abstract directly supports the combined diagnostic findings.
treatments:
- name: Prednisone and azathioprine immunosuppression
  description: >-
    Prednisone with azathioprine has been used as traditional immunosuppression;
    it can induce remission, but relapses and prolonged treatment are common.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: prednisone
      term:
        id: CHEBI:8382
        label: prednisone
    - preferred_term: azathioprine
      term:
        id: CHEBI:2948
        label: azathioprine
  target_phenotypes:
  - preferred_term: Giant cell hepatitis
    term:
      id: HP:0200084
      label: Giant cell hepatitis
  - preferred_term: Autoimmune hemolytic anemia
    term:
      id: HP:0001890
      label: Autoimmune hemolytic anemia
  evidence:
  - reference: PMID:21349541
    reference_title: "Giant cell hepatitis with autoimmune hemolytic anemia in early childhood: long-term outcome in 16 children."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Treatment with prednisone and azathioprine, plus, in three children,
      cyclosporine, resulted in complete remission in eight, partial remission in
      six, and failure in two.
    explanation: This cohort supports prednisone/azathioprine-based immunosuppression as a remission-inducing treatment with incomplete response.
  - reference: PMID:21349541
    reference_title: "Giant cell hepatitis with autoimmune hemolytic anemia in early childhood: long-term outcome in 16 children."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Relapses of hepatitis and/or anemia occurred in 11 and 10 children,
      respectively, requiring prolonged high levels of immunosuppression, and
      splenectomy or Rituximab, respectively.
    explanation: This supports the relapsing course and frequent need for prolonged or escalated treatment.
- name: Rituximab
  description: >-
    Rituximab is an anti-CD20 monoclonal antibody that targets B lymphocytes and
    is supported by disease-specific series for refractory or severe disease.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: rituximab
      term:
        id: NCIT:C1702
        label: Rituximab
  target_mechanisms:
  - target: Systemic B-cell autoimmunity
    treatment_effect: INHIBITS
    description: Rituximab depletes CD20-positive B cells implicated in systemic humoral autoimmunity.
  - target: Complement-mediated hepatocyte injury
    treatment_effect: INHIBITS
    description: B-cell depletion is expected to reduce upstream antibody-driven complement injury.
  evidence:
  - reference: PMID:25201797
    reference_title: "Anti-CD20 treatment of giant cell hepatitis with autoimmune hemolytic anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We describe here the detailed clinical evolution of 4 children with GCH-AHA
      who showed a complete response to rituximab.
    explanation: This case series directly supports rituximab response in GCH-AHA.
  - reference: PMID:23969541
    reference_title: "Humoral immune mechanism of liver injury in giant cell hepatitis with autoimmune hemolytic anemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our findings support B-cell-directed immunotherapy as a first-line treatment
      of GCH-AHA.
    explanation: The mechanistic study links complement/B-cell pathology to B-cell-directed treatment.
- name: Intravenous immunoglobulin
  description: >-
    IVIG can reduce liver enzyme activity and help maintain remission as an
    adjunct, but repeated infusions have temporary efficacy and are not routine
    long-term therapy.
  treatment_term:
    preferred_term: Intravenous Immunoglobulin Therapy
    term:
      id: NCIT:C121331
      label: Intravenous Immunoglobulin Therapy
    therapeutic_agent:
    - preferred_term: Therapeutic Immune Globulin
      term:
        id: NCIT:C2701
        label: Therapeutic Immune Globulin
  target_phenotypes:
  - preferred_term: Elevated circulating hepatic transaminase concentration
    term:
      id: HP:0002910
      label: Elevated circulating hepatic transaminase concentration
  evidence:
  - reference: PMID:26138133
    reference_title: "Efficacy of intravenous immunoglobulin therapy in giant cell hepatitis with autoimmune hemolytic anemia: A multicenter study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      IVIg infusions as first-line therapy associated with prednisone and other
      immunosuppressive drugs significantly (P=0.04) reduced the aminotransferase
      activity in all patients and normalized prothrombin activity in the only
      patient with severe liver dysfunction.
    explanation: This multicenter series supports IVIG-associated improvement in liver biochemical activity.
  - reference: PMID:26138133
    reference_title: "Efficacy of intravenous immunoglobulin therapy in giant cell hepatitis with autoimmune hemolytic anemia: A multicenter study."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Repeated IVIg infusions may help maintain remission, however, due to their
      temporary efficacy, they should not be routinely employed.
    explanation: This supports IVIG as useful but temporary adjunctive therapy rather than routine maintenance.
- name: Liver transplantation
  description: >-
    Liver transplantation has been used for advanced liver disease, but the
    syndrome is primarily managed by immune control when possible.
  treatment_term:
    preferred_term: organ transplantation
    term:
      id: MAXO:0010039
      label: organ transplantation
  target_phenotypes:
  - preferred_term: Hepatic failure
    term:
      id: HP:0001399
      label: Hepatic failure
  evidence:
  - reference: PMID:21349541
    reference_title: "Giant cell hepatitis with autoimmune hemolytic anemia in early childhood: long-term outcome in 16 children."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      One child is alive 9 years after liver transplantation.
    explanation: This supports liver transplantation as a possible survival-associated intervention in selected severe cases, but not as routine first-line therapy.
- name: Splenectomy
  description: >-
    Splenectomy has been used as an escalation option for relapsing or refractory
    hemolytic anemia in the long-term cohort.
  treatment_term:
    preferred_term: splenectomy
    term:
      id: MAXO:0001077
      label: splenectomy
  target_phenotypes:
  - preferred_term: Autoimmune hemolytic anemia
    term:
      id: HP:0001890
      label: Autoimmune hemolytic anemia
  evidence:
  - reference: PMID:21349541
    reference_title: "Giant cell hepatitis with autoimmune hemolytic anemia in early childhood: long-term outcome in 16 children."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Relapses of hepatitis and/or anemia occurred in 11 and 10 children,
      respectively, requiring prolonged high levels of immunosuppression, and
      splenectomy or Rituximab, respectively.
    explanation: This cohort abstract names splenectomy as an escalation treatment used for relapsing anemia.
progression:
- phase: Relapsing hepatitis and anemia
  notes: >-
    The clinical course often involves relapse of either liver disease or
    hemolytic anemia, requiring prolonged or escalated immunosuppression.
  evidence:
  - reference: PMID:21349541
    reference_title: "Giant cell hepatitis with autoimmune hemolytic anemia in early childhood: long-term outcome in 16 children."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Relapses of hepatitis and/or anemia occurred in 11 and 10 children,
      respectively, requiring prolonged high levels of immunosuppression, and
      splenectomy or Rituximab, respectively.
    explanation: This long-term cohort directly supports a relapsing disease course.
- phase: Mortality from severe systemic complications
  notes: >-
    Severe cases may be fatal, including death from sepsis or multiple organ
    failure in long-term cohort follow-up.
  evidence:
  - reference: PMID:21349541
    reference_title: "Giant cell hepatitis with autoimmune hemolytic anemia in early childhood: long-term outcome in 16 children."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Four children died of sepsis or multiple organ failure.
    explanation: This cohort directly supports mortality from severe complications.
animal_models: []
clinical_trials: []
datasets: []
references:
- reference: DOI:10.1016/j.jpeds.2010.12.050
  title: "Giant cell hepatitis with autoimmune hemolytic anemia in early childhood: long-term outcome in 16 children."
  found_in:
  - Giant_Cell_Hepatitis_With_Autoimmune_Hemolytic_Anemia-deep-research-falcon.md
  findings:
  - statement: Long-term cohort of 16 children with GCH-AIHA.
    supporting_text: "Giant cell hepatitis with autoimmune hemolytic anemia in early childhood: long-term outcome in 16 children."
- reference: DOI:10.1097/mpg.0b013e3182a98dbe
  title: Humoral immune mechanism of liver injury in giant cell hepatitis with autoimmune hemolytic anemia.
  found_in:
  - Giant_Cell_Hepatitis_With_Autoimmune_Hemolytic_Anemia-deep-research-falcon.md
  findings:
  - statement: Humoral and complement-mediated liver injury mechanism in GCH-AIHA.
    supporting_text: Humoral immune mechanism of liver injury in giant cell hepatitis with autoimmune hemolytic anemia.
- reference: DOI:10.1016/j.clinre.2015.03.009
  title: "Efficacy of intravenous immunoglobulin therapy in giant cell hepatitis with autoimmune hemolytic anemia: A multicenter study."
  found_in:
  - Giant_Cell_Hepatitis_With_Autoimmune_Hemolytic_Anemia-deep-research-falcon.md
  findings:
  - statement: Multicenter IVIG treatment series in GCH-AIHA.
    supporting_text: "Efficacy of intravenous immunoglobulin therapy in giant cell hepatitis with autoimmune hemolytic anemia: A multicenter study."
- reference: DOI:10.1542/peds.2014-0032
  title: Anti-CD20 treatment of giant cell hepatitis with autoimmune hemolytic anemia.
  found_in:
  - Giant_Cell_Hepatitis_With_Autoimmune_Hemolytic_Anemia-deep-research-falcon.md
  findings:
  - statement: Anti-CD20 treatment series supporting rituximab use in GCH-AIHA.
    supporting_text: Anti-cd20 treatment of giant cell hepatitis with autoimmune hemolytic anemia.
- reference: DOI:10.5223/pghn.2020.23.2.180
  title: Successful Treatment of a Korean Infant with Giant Cell Hepatitis with Autoimmune Hemolytic Anemia Using Rituximab.
  found_in:
  - Giant_Cell_Hepatitis_With_Autoimmune_Hemolytic_Anemia-deep-research-falcon.md
  findings:
  - statement: Infant GCH-AIHA case treated with rituximab.
    supporting_text: Successful treatment of a korean infant with giant cell hepatitis with autoimmune hemolytic anemia using rituximab.
- reference: DOI:10.3109/15513819409022027
  title: Coombs-positive autoimmune hemolytic anemia and postinfantile giant cell hepatitis in children.
  found_in:
  - Giant_Cell_Hepatitis_With_Autoimmune_Hemolytic_Anemia-deep-research-falcon.md
  findings:
  - statement: Classic pediatric pathology report of Coombs-positive AIHA with postinfantile giant cell hepatitis.
    supporting_text: Coombs-positive autoimmune hemolytic anemia and postinfantile giant cell hepatitis in children.
- reference: DOI:10.1097/mpg.0000000000000270
  title: "Giant cell hepatitis with autoimmune hemolytic anemia in children: proposal for therapeutic approach."
  found_in:
  - Giant_Cell_Hepatitis_With_Autoimmune_Hemolytic_Anemia-deep-research-falcon.md
  findings:
  - statement: Severe pediatric GCH-AIHA series proposing rituximab therapeutic approach.
    supporting_text: "Giant cell hepatitis with autoimmune hemolytic anemia in children: proposal for therapeutic approach."
- reference: DOI:10.1177/0009922810379501
  title: "Giant cell hepatitis with autoimmune hemolytic anemia: a case report and review of pediatric literature."
  found_in:
  - Giant_Cell_Hepatitis_With_Autoimmune_Hemolytic_Anemia-deep-research-falcon.md
  findings:
  - statement: Pediatric case report and literature review of GCH-AIHA.
    supporting_text: "Giant cell hepatitis with autoimmune hemolytic anemia: a case report and review of pediatric literature."
- reference: DOI:10.1111/ped.12874
  title: Giant cell hepatitis with autoimmune hemolytic anemia in a Korean infant.
  found_in:
  - Giant_Cell_Hepatitis_With_Autoimmune_Hemolytic_Anemia-deep-research-falcon.md
  findings:
  - statement: Korean infant case report of GCH-AIHA.
    supporting_text: Giant cell hepatitis with autoimmune hemolytic anemia in a Korean infant.
- reference: DOI:10.5152/tjh.2010.55
  title: "Autoimmune hemolytic anemia and giant cell hepatitis: Report of three infants."
  found_in:
  - Giant_Cell_Hepatitis_With_Autoimmune_Hemolytic_Anemia-deep-research-falcon.md
  findings:
  - statement: Three-infant report of autoimmune hemolytic anemia and giant cell hepatitis.
    supporting_text: "Autoimmune hemolytic anemia and giant cell hepatitis: Report of three infants."
review_notes: >-
  Falcon deep research found no disease-specific clinical trials or genetic
  etiology. The entry therefore emphasizes the best-supported pediatric clinical
  series, pathology series, humoral/complement mechanism, IVIG data, and
  rituximab treatment reports.
📚

References & Deep Research

References

10
DOI:10.1016/j.jpeds.2010.12.050
Giant cell hepatitis with autoimmune hemolytic anemia in early childhood: long-term outcome in 16 children.
1 finding
Long-term cohort of 16 children with GCH-AIHA.
"Giant cell hepatitis with autoimmune hemolytic anemia in early childhood: long-term outcome in 16 children."
DOI:10.1097/mpg.0b013e3182a98dbe
Humoral immune mechanism of liver injury in giant cell hepatitis with autoimmune hemolytic anemia.
1 finding
Humoral and complement-mediated liver injury mechanism in GCH-AIHA.
"Humoral immune mechanism of liver injury in giant cell hepatitis with autoimmune hemolytic anemia."
DOI:10.1016/j.clinre.2015.03.009
Efficacy of intravenous immunoglobulin therapy in giant cell hepatitis with autoimmune hemolytic anemia: A multicenter study.
1 finding
Multicenter IVIG treatment series in GCH-AIHA.
"Efficacy of intravenous immunoglobulin therapy in giant cell hepatitis with autoimmune hemolytic anemia: A multicenter study."
DOI:10.1542/peds.2014-0032
Anti-CD20 treatment of giant cell hepatitis with autoimmune hemolytic anemia.
1 finding
Anti-CD20 treatment series supporting rituximab use in GCH-AIHA.
"Anti-cd20 treatment of giant cell hepatitis with autoimmune hemolytic anemia."
DOI:10.5223/pghn.2020.23.2.180
Successful Treatment of a Korean Infant with Giant Cell Hepatitis with Autoimmune Hemolytic Anemia Using Rituximab.
1 finding
Infant GCH-AIHA case treated with rituximab.
"Successful treatment of a korean infant with giant cell hepatitis with autoimmune hemolytic anemia using rituximab."
DOI:10.3109/15513819409022027
Coombs-positive autoimmune hemolytic anemia and postinfantile giant cell hepatitis in children.
1 finding
Classic pediatric pathology report of Coombs-positive AIHA with postinfantile giant cell hepatitis.
"Coombs-positive autoimmune hemolytic anemia and postinfantile giant cell hepatitis in children."
DOI:10.1097/mpg.0000000000000270
Giant cell hepatitis with autoimmune hemolytic anemia in children: proposal for therapeutic approach.
1 finding
Severe pediatric GCH-AIHA series proposing rituximab therapeutic approach.
"Giant cell hepatitis with autoimmune hemolytic anemia in children: proposal for therapeutic approach."
DOI:10.1177/0009922810379501
Giant cell hepatitis with autoimmune hemolytic anemia: a case report and review of pediatric literature.
1 finding
Pediatric case report and literature review of GCH-AIHA.
"Giant cell hepatitis with autoimmune hemolytic anemia: a case report and review of pediatric literature."
DOI:10.1111/ped.12874
Giant cell hepatitis with autoimmune hemolytic anemia in a Korean infant.
1 finding
Korean infant case report of GCH-AIHA.
"Giant cell hepatitis with autoimmune hemolytic anemia in a Korean infant."
DOI:10.5152/tjh.2010.55
Autoimmune hemolytic anemia and giant cell hepatitis: Report of three infants.
1 finding
Three-infant report of autoimmune hemolytic anemia and giant cell hepatitis.
"Autoimmune hemolytic anemia and giant cell hepatitis: Report of three infants."

Deep Research

1
Falcon ▸
1. Disease Information
Edison Scientific Literature 43 citations 2026-05-06T22:18:02.304566

1. Disease Information

1.1 Definition / overview

Giant cell hepatitis with autoimmune hemolytic anemia (GCH-AHA/GCH-AIHA) is a rare pediatric syndrome characterized by the association of (i) Coombs-positive autoimmune hemolytic anemia and (ii) biopsy-proven giant cell hepatitis, typically presenting beyond the neonatal period and often progressing with relapses. (maggiore2011giantcellhepatitis pages 1-2, marsalli2016efficacyofintravenous pages 1-2, paganelli2014anticd20treatmentof pages 1-2)

Direct abstract quote (definition framing): In the Pediatrics case series, the abstract begins: “Giant cell hepatitis with autoimmune hemolytic anemia (GCH-AHA) is a rare autoimmune disease of infancy characterized by severe liver disease associated with Coombs-positive hemolytic anemia.” (paganelli2014anticd20treatmentof pages 1-2)

1.2 Synonyms / alternative names used in the literature

  • Giant cell hepatitis with autoimmune hemolytic anemia (GCH-AHA) (paganelli2014anticd20treatmentof pages 1-2)
  • Giant cell hepatitis with autoimmune hemolytic anemia (GCH-AIHA) (usage varies by author; concept consistent across cohorts) (maggiore2011giantcellhepatitis pages 1-2, marsalli2016efficacyofintravenous pages 1-2)
  • Coombs-positive autoimmune hemolytic anemia with postinfantile/infantile giant cell hepatitis (perezatayde1994coombspositiveautoimmunehemolytic pages 1-4)

1.3 Disease identifiers (OMIM/Orphanet/ICD/MeSH/MONDO)

Within the retrieved full texts, explicit OMIM, Orphanet, ICD-10/ICD-11, MeSH, or MONDO identifiers were not present; therefore, these identifiers cannot be asserted from this evidence set.

1.4 Evidence source type

Evidence is largely derived from case reports and small pediatric series, plus one retrospective multicenter observational study of IVIG and a long-term outcome cohort of 16 children. (maggiore2011giantcellhepatitis pages 1-2, marsalli2016efficacyofintravenous pages 1-2)

2. Etiology

2.1 Primary causes (current understanding)

The etiology is not established as genetic; instead, available evidence supports an immune-mediated (autoimmune) cause, specifically a humoral (B-cell/IgG) and complement-mediated injury mechanism in the liver, alongside antibody/complement-mediated hemolysis. (whitington2014humoralimmunemechanism pages 2-3, marsalli2016efficacyofintravenous pages 1-2)

2.2 Risk factors

Age is the dominant epidemiologic risk factor: most cases occur in infancy/early childhood. (maggiore2011giantcellhepatitis pages 1-2, whitington2014humoralimmunemechanism pages 2-3)

Potential triggers/associations are inconsistently reported. For example, one cohort noted an infectious serology signal (parvovirus) in an individual patient without proving causality (reported in a case series context). (bakula2014giantcellhepatitis pages 1-3)

2.3 Protective factors

No protective genetic or environmental factors were identified in the retrieved disease-specific literature.

2.4 Gene–environment interactions

No gene–environment interaction evidence was identified in the retrieved literature.

3. Phenotypes

3.1 Core clinical phenotypes and suggested HPO terms

Below are recurring phenotypes with suggested HPO mappings based on cohort/case-series descriptions.

Hemolysis/AIHA phenotype complex (often first): * Pallor (HP:0000980) * Jaundice (HP:0000952) * Hemolytic anemia (HP:0001878) * Positive direct antiglobulin test / Coombs positive hemolysis (no single HPO term; can map to laboratory abnormality plus “autoimmune hemolytic anemia” concept) * Splenomegaly (HP:0001744) * Hepatosplenomegaly (HP:0001433) * Fever (HP:0001945)

In a 16-child cohort at diagnosis: jaundice 14/16, hepatomegaly 16/16, splenomegaly 6/16, pallor 9/16, fever 8/16. (maggiore2011giantcellhepatitis pages 1-2)

Liver phenotype complex (often later, relapsing): * Hepatomegaly (HP:0002240) * Hepatitis (HP:0012115) * Cholestasis (HP:0002904) * Hyperbilirubinemia (HP:0002904/HP:0002910 context-dependent) * Elevated transaminases (HP:0002910) * Liver fibrosis / cirrhosis (HP:0001395) * Acute liver failure can occur in some patients (HP:0006557), though not universal (whitington2014humoralimmunemechanism pages 2-3)

Temporal phenotype relationship: hemolytic anemia may precede hepatitis by weeks to months; one review-level synthesis described hepatitis appearing 1 week to 15 months after hemolysis onset (often 1–2 months). (raj2011giantcellhepatitis pages 1-2, kim2020successfultreatmentof pages 2-4)

3.2 Laboratory phenotypes and suggested HPO terms

From cohort/case evidence: * Low hemoglobin (HP:0001903): median Hb 6.7 g/dL in the 16-child cohort (maggiore2011giantcellhepatitis pages 1-2) * High reticulocyte count (HP:0001898): median reticulocytes 207,000/mL in the 16-child cohort (maggiore2011giantcellhepatitis pages 1-2) * Hyperbilirubinemia (HP:0002904): median total bilirubin 13.5 mg/dL, direct 11 mg/dL in the 16-child cohort (maggiore2011giantcellhepatitis pages 1-2) * Markedly elevated ALT/AST (HP:0002910): ALT reported as 45× ULN median in the 16-child cohort; extreme values reported in case reports (maggiore2011giantcellhepatitis pages 1-2, raj2011giantcellhepatitis pages 1-2)

3.3 Quality of life impact

Disease is described as severe, requiring prolonged immunosuppression and repeated hospitalization for relapses and infections; formal QoL instruments (e.g., PedsQL) were not reported in the retrieved texts. (maggiore2011giantcellhepatitis pages 1-2, marsalli2016efficacyofintravenous pages 1-2)

4. Genetic / Molecular Information

4.1 Causal genes

No causal genes or recurrent pathogenic variants were identified in the retrieved disease-specific literature; current evidence supports an immune-mediated syndrome rather than a monogenic disorder.

4.2 Pathogenic variants / modifier genes / epigenetics / chromosomal abnormalities

No disease-specific evidence was found in the retrieved texts.

5. Environmental Information

5.1 Environmental/lifestyle factors

No environmental or lifestyle risk factors were established in the retrieved texts.

5.2 Infectious agents

Infectious workups are often described as negative in pediatric reports; occasional associations (e.g., parvovirus serology in an individual) do not establish causality. (bakula2014giantcellhepatitis pages 1-3, cho2016giantcellhepatitis pages 1-2)

6. Mechanism / Pathophysiology

6.1 Key mechanistic concept

A central, disease-defining mechanistic insight is that liver injury in GCH-AIHA appears to be antibody/complement (humoral) mediated, differing from classic T-cell–predominant autoimmune hepatitis (AIH). This is supported by: * Pan-lobular hepatocyte C5b-9 (membrane attack complex) deposition in GCH-AHA biopsies (high-grade in all cases in one mechanistic series) (whitington2014humoralimmunemechanism pages 2-3, whitington2014humoralimmunemechanism pages 1-1) * A lobular inflammatory pattern enriched for macrophages/neutrophils rather than portal/periportal lymphocyte–rich inflammation typical of AIH (whitington2014humoralimmunemechanism pages 3-6) * Clinical refractoriness to “standard” AIH regimens in many patients and strong responses to B-cell depletion (rituximab) (whitington2014humoralimmunemechanism pages 2-3, paganelli2014anticd20treatmentof pages 1-2)

6.2 Causal chain (upstream → downstream)

Proposed causal chain (human biopsy and clinical-response supported): 1) B-cell–derived IgG binds an (unknown) hepatocyte target antigen (upstream trigger not yet defined). (whitington2014humoralimmunemechanism pages 6-6, whitington2014humoralimmunemechanism pages 1-1) 2) IgG triggers classical complement pathway activation on hepatocytes, leading to deposition of C5b-9; Whitington et al. note the staining intensity is a marker of complement-mediated injury (“The degree of C5b-9 staining…is indicative of the degree of complement-mediated cell injury”). (whitington2014humoralimmunemechanism pages 2-3) 3) Complement split products (e.g., C3a/C5a) recruit/activate innate immune cells, producing lobular inflammation dominated by macrophages and neutrophils and hepatocyte necroinflammation. (whitington2014humoralimmunemechanism pages 3-6, whitington2014humoralimmunemechanism pages 6-6) 4) Injured hepatocytes undergo giant cell transformation (multinucleation/fusion), a histologic hallmark. (perezatayde1994coombspositiveautoimmunehemolytic pages 1-4, whitington2014humoralimmunemechanism pages 3-6) 5) In parallel, antibody/complement activity produces Coombs-positive hemolytic anemia, sometimes preceding the hepatitis, reinforcing a systemic humoral immune disorder phenotype. (marsalli2016efficacyofintravenous pages 1-2, maggiore2011giantcellhepatitis pages 1-2)

6.3 Suggested ontology mappings

GO biological process terms (suggested): * complement activation, classical pathway * regulation of complement activation * B cell mediated immunity * antibody-mediated immune response * inflammatory response * macrophage activation * neutrophil chemotaxis * liver regeneration * hepatic fibrosis

Cell Ontology (CL) terms (suggested): * hepatocyte * B cell (CD20+) * macrophage (CD68+) * neutrophil * Kupffer cell (liver macrophage; if specifically described)

UBERON anatomy (suggested): * liver * hepatic lobule * spleen * bone marrow * blood

7. Anatomical Structures Affected

7.1 Organ level

Primary: liver (giant cell hepatitis, cholestasis, fibrosis/cirrhosis risk). (perezatayde1994coombspositiveautoimmunehemolytic pages 1-4, maggiore2011giantcellhepatitis pages 1-2)

Secondary/related: hematologic system (autoimmune hemolytic anemia; often hepatosplenomegaly). (maggiore2011giantcellhepatitis pages 1-2, whitington2014humoralimmunemechanism pages 2-3)

7.2 Tissue and cell level

  • Hepatic parenchyma (lobular architecture disturbance, giant hepatocytes, fibrosis; minimal portal pathology in some mechanistic descriptions) (perezatayde1994coombspositiveautoimmunehemolytic pages 1-4, whitington2014humoralimmunemechanism pages 1-2)
  • Immune infiltrate pattern differing from AIH: relatively fewer portal lymphocytes with more lobular macrophages/neutrophils in GCH-AHA (whitington2014humoralimmunemechanism pages 3-6)

8. Temporal Development

8.1 Onset

Typically infancy/early childhood. Median age 6 months in a 16-child cohort; mechanistic series range 4–52 months. (maggiore2011giantcellhepatitis pages 1-2, whitington2014humoralimmunemechanism pages 2-3)

8.2 Progression and course

Course is often relapsing and may require years of immunosuppression. In the 16-child cohort, relapses occurred in 11/16 (hepatitis) and 10/16 (anemia); treatment could eventually be stopped after a mean 6 years in some patients with sustained remission. (maggiore2011giantcellhepatitis pages 1-2)

9. Inheritance and Population

9.1 Epidemiology

Population-level prevalence/incidence estimates were not available in the retrieved texts; the syndrome is repeatedly described as very rare, with literature case counts increasing over time (e.g., 18 cases reported before 2011 cohort; approximately 50 cases by 2015; “<100 reported cases” by 2020). (maggiore2011giantcellhepatitis pages 1-2, cho2016giantcellhepatitis pages 1-2, kim2020successfultreatmentof pages 2-4)

9.2 Inheritance

No inherited pattern is established from available evidence.

10. Diagnostics

10.1 Core diagnostic components

A. Hematology: direct antiglobulin (Coombs/DAT) positivity demonstrating autoimmune hemolysis (commonly IgG±complement). (maggiore2011giantcellhepatitis pages 1-2, marsalli2016efficacyofintravenous pages 1-2)

B. Hepatology: liver biochemistry consistent with hepatitis/cholestasis plus liver biopsy showing diffuse giant cell transformation and associated injury/fibrosis patterns. (perezatayde1994coombspositiveautoimmunehemolytic pages 1-4, maggiore2011giantcellhepatitis pages 1-2)

C. Exclusion of other causes: cohorts describe exclusion of viral, metabolic, toxic, and cholestatic etiologies as part of case definition/selection. (maggiore2011giantcellhepatitis pages 1-2)

10.2 Key histopathology

A classic early report describes: “loss of lobular architecture with diffuse giant cell transformation of hepatocytes and portal and pericellular fibrosis.” (perezatayde1994coombspositiveautoimmunehemolytic pages 1-4)

Mechanistic work emphasizes complement immunostaining: high-grade hepatocyte C5b-9 deposition as evidence for complement-mediated injury and potential stratification for B-cell–targeted therapy. (whitington2014humoralimmunemechanism pages 2-3, whitington2014humoralimmunemechanism pages 6-6)

10.3 Differential diagnosis (from available evidence)

The literature emphasizes distinguishing GCH-AHA from classic pediatric autoimmune hepatitis (different autoantibody patterns, different histology/immune infiltrates, different treatment responsiveness). (whitington2014humoralimmunemechanism pages 2-3, whitington2014humoralimmunemechanism pages 1-1)

11. Outcome / Prognosis

11.1 Mortality, transplant, long-term outcomes

Outcomes can be severe: * In the 16-child long-term cohort: 4/16 died (sepsis or multiple organ failure) and 1/16 survived after liver transplantation (alive 9 years post-transplant). (maggiore2011giantcellhepatitis pages 1-2) * Earlier literature summarized within that cohort reported mortality or need for liver transplantation of 39% in reported cases at that time. (maggiore2011giantcellhepatitis pages 1-2) * In a 6-case mechanistic series: only 1/6 achieved remission with standard therapy; 1 died and 1 underwent transplantation; 3/3 rituximab-treated patients achieved remission. (whitington2014humoralimmunemechanism pages 2-3)

11.2 Prognostic factors

A small 3-infant report concluded: “We conclude that serum ferritin at diagnosis may be used for prediction of the outcome.” However, thresholds and validation were not available in the extracted evidence. (marsalli2016efficacyofintravenous pages 2-3)

A dominant practical prognostic concern across cohorts is infection risk during prolonged immunosuppression (death from sepsis reported). (maggiore2011giantcellhepatitis pages 1-2)

12. Treatment

12.1 Immunosuppression (historical backbone): corticosteroids + azathioprine

In the 16-child cohort, prednisone + azathioprine (± cyclosporine) led to complete remission in 8/16, partial remission in 6/16, and failure in 2/16, but relapses were common (11/16 hepatitis; 10/16 anemia). (maggiore2011giantcellhepatitis pages 1-2)

Suggested MAXO terms (examples): immunosuppressive therapy; glucocorticoid therapy; azathioprine therapy.

12.2 IVIG (immunomodulatory) as adjunct / steroid-sparing

In a multicenter retrospective series of 7 children, IVIG (0.5–2 g/kg; sequential monthly dosing in 5/7) significantly reduced aminotransferases (P=0.04) and showed steroid-sparing benefit, but relapse occurred in all patients over follow-up (hemolysis and/or liver disease). (marsalli2016efficacyofintravenous pages 1-2, marsalli2016efficacyofintravenous pages 6-7)

Suggested MAXO terms: intravenous immunoglobulin therapy.

12.3 Rituximab (anti-CD20) B-cell depletion: targeted therapy with strong signal

Multiple series report strong responses: * Whitington et al.: rituximab induced remission in 3/3 refractory patients. (whitington2014humoralimmunemechanism pages 2-3) * Paganelli et al. (Pediatrics): “complete response” in 4 children, with steroid weaning in all; several doses and 5–11 maintenance injections in severe cases; no infections/side effects reported in that series. (paganelli2014anticd20treatmentof pages 1-2)

Suggested MAXO terms: anti-CD20 monoclonal antibody therapy; B-cell depletion therapy.

12.4 Other immunomodulatory/second-line approaches

Reports include cyclosporine, tacrolimus, mycophenolate, cyclophosphamide, plasmapheresis, splenectomy, and (rarely) stem-cell transplantation in complex immune-dysregulation scenarios; evidence is limited and heterogeneous. (bakula2014giantcellhepatitis pages 1-3, kim2020successfultreatmentof pages 5-6, raj2011giantcellhepatitis pages 1-2)

12.5 Liver transplantation

Transplantation has been used for end-stage liver disease, but recurrence/relapse concerns exist. One child in the 16-patient cohort was alive 9 years post-transplant. (maggiore2011giantcellhepatitis pages 1-2)

A later case review table notes that transplantation has been complicated by relapse/rejection and “is no longer recommended presently” (as a routine strategy), emphasizing immune control instead where possible. (kim2020successfultreatmentof pages 5-6)

12.6 Clinical trials

ClinicalTrials.gov searches in this environment did not yield clear, disease-specific interventional trials for GCH-AIHA.

13. Prevention

No primary prevention strategies are established due to unclear triggers and extreme rarity. Secondary/tertiary prevention in practice focuses on relapse monitoring and infection prevention during immunosuppression (not quantified in retrieved sources). (maggiore2011giantcellhepatitis pages 1-2)

14. Other Species / Natural Disease

No naturally occurring animal disease analogs were identified in the retrieved texts.

15. Model Organisms

No dedicated model organism systems for this syndrome were described in the retrieved texts. Mechanistic reasoning references complement biology and includes supportive statements from experimental complement-depletion contexts, but disease-specific engineered models were not presented in the available extracts. (whitington2014humoralimmunemechanism pages 6-6)

Current applications and real-world implementation (clinical practice implications)

1) Diagnosis in real-world settings relies on recognizing the syndrome pattern (DAT-positive hemolysis plus progressive cholestatic hepatitis) and confirming with liver biopsy and exclusion of other causes. (maggiore2011giantcellhepatitis pages 1-2) 2) Treatment implementation is increasingly aligned with the mechanistic model: conventional immunosuppression may induce remission but relapse is common, while B-cell depletion (rituximab) has repeatedly induced remission in refractory disease and is supported by complement-pathology findings. (whitington2014humoralimmunemechanism pages 2-3, paganelli2014anticd20treatmentof pages 1-2)

Limitations of this report (evidence availability)

  • Disease-specific 2023–2024 primary studies were not accessible via the current retrieval tools; thus, up-to-date (2023–2024) GCH-AIHA-specific statistics (e.g., contemporary response rates to rituximab regimens) could not be extracted here.
  • Standard ontology identifiers (MONDO/OMIM/Orphanet/MeSH/ICD) were not present in the retrieved full texts; they should be sourced from dedicated ontology databases in a separate curation step.
  • Image extraction from key papers failed in this environment, so no histology figure panels could be provided.

Key referenced sources (publication date, URL)

  • Perez-Atayde AR et al. 1994. Coombs-Positive Autoimmune Hemolytic Anemia and Postinfantile Giant Cell Hepatitis in Children. https://doi.org/10.3109/15513819409022027 (perezatayde1994coombspositiveautoimmunehemolytic pages 1-4)
  • Maggiore G et al. 2011-07. Giant cell hepatitis with autoimmune hemolytic anemia in early childhood: long-term outcome in 16 children. https://doi.org/10.1016/j.jpeds.2010.12.050 (maggiore2011giantcellhepatitis pages 1-2)
  • Raj S et al. 2011-03. Giant Cell Hepatitis With Autoimmune Hemolytic Anemia: A Case Report and Review of Pediatric Literature. https://doi.org/10.1177/0009922810379501 (raj2011giantcellhepatitis pages 1-2)
  • Whitington PF et al. 2014-01. Humoral Immune Mechanism of Liver Injury in Giant Cell Hepatitis With Autoimmune Hemolytic Anemia. https://doi.org/10.1097/MPG.0b013e3182a98dbe (whitington2014humoralimmunemechanism pages 2-3)
  • Paganelli M et al. 2014-10. Anti-CD20 Treatment of Giant Cell Hepatitis With Autoimmune Hemolytic Anemia. https://doi.org/10.1542/peds.2014-0032 (paganelli2014anticd20treatmentof pages 1-2)
  • Marsalli G et al. 2016-02. Efficacy of intravenous immunoglobulin therapy in giant cell hepatitis with autoimmune hemolytic anemia: A multicenter study. https://doi.org/10.1016/j.clinre.2015.03.009 (marsalli2016efficacyofintravenous pages 1-2)
  • Kim YH et al. 2020-03. Successful Treatment … Using Rituximab https://doi.org/10.5223/pghn.2020.23.2.180 (kim2020successfultreatmentof pages 2-4)

References

  1. (maggiore2011giantcellhepatitis pages 1-2): Giuseppe Maggiore, Marco Sciveres, Monique Fabre, Laura Gori, Lucia Pacifico, Massimo Resti, Jean-Jacques Choulot, Emmanuel Jacquemin, and Olivier Bernard. Giant cell hepatitis with autoimmune hemolytic anemia in early childhood: long-term outcome in 16 children. The Journal of pediatrics, 159 1:127-132.e1, Jul 2011. URL: https://doi.org/10.1016/j.jpeds.2010.12.050, doi:10.1016/j.jpeds.2010.12.050. This article has 72 citations.

  2. (whitington2014humoralimmunemechanism pages 2-3): Peter F. Whitington, Miriam B. Vos, Lee M. Bass, Hector Melin‐Aldana, Rene Romero, Claude C. Roy, and Fernando Alvarez. Humoral immune mechanism of liver injury in giant cell hepatitis with autoimmune hemolytic anemia. Journal of Pediatric Gastroenterology and Nutrition, 58:74–80, Jan 2014. URL: https://doi.org/10.1097/mpg.0b013e3182a98dbe, doi:10.1097/mpg.0b013e3182a98dbe. This article has 39 citations and is from a peer-reviewed journal.

  3. (marsalli2016efficacyofintravenous pages 1-2): Giulia Marsalli, Silvia Nastasio, Marco Sciveres, Pier Luigi Calvo, Ugo Ramenghi, Simona Gatti, Veronica Albano, Sara Lega, Alessandro Ventura, and Giuseppe Maggiore. Efficacy of intravenous immunoglobulin therapy in giant cell hepatitis with autoimmune hemolytic anemia: a multicenter study. Clinics and research in hepatology and gastroenterology, 40 1:83-9, Feb 2016. URL: https://doi.org/10.1016/j.clinre.2015.03.009, doi:10.1016/j.clinre.2015.03.009. This article has 24 citations and is from a peer-reviewed journal.

  4. (raj2011giantcellhepatitis pages 1-2): Shashi Raj, Thomas Stephen, and Robert F. Debski. Giant cell hepatitis with autoimmune hemolytic anemia: a case report and review of pediatric literature. Clinical Pediatrics, 50:357-359, Mar 2011. URL: https://doi.org/10.1177/0009922810379501, doi:10.1177/0009922810379501. This article has 18 citations and is from a peer-reviewed journal.

  5. (kim2020successfultreatmentof pages 2-4): Young Ho Kim, Ju Whi Kim, Eun Joo Lee, Gyeong Hoon Kang, Hyoung Jin Kang, Jin Soo Moon, and Jae Sung Ko. Successful treatment of a korean infant with giant cell hepatitis with autoimmune hemolytic anemia using rituximab. Pediatric Gastroenterology, Hepatology & Nutrition, 23:180-187, Mar 2020. URL: https://doi.org/10.5223/pghn.2020.23.2.180, doi:10.5223/pghn.2020.23.2.180. This article has 9 citations and is from a peer-reviewed journal.

  6. (cho2016giantcellhepatitis pages 1-2): Myung Hyun Cho, Hee Sun Park, Hye Seung Han, and Sun Hwan Bae. Giant cell hepatitis with autoimmune hemolytic anemia in a korean infant. Pediatrics International, 58:628-631, Feb 2016. URL: https://doi.org/10.1111/ped.12874, doi:10.1111/ped.12874. This article has 10 citations and is from a peer-reviewed journal.

  7. (perezatayde1994coombspositiveautoimmunehemolytic pages 1-4): Antonio R. Perez-Atayde, Scott M. Sirlin, and Maureen Jonas. Coombs-positive autoimmune hemolytic anemia and postinfantile giant cell hepatitis in children. Pediatric pathology, 14 1:69-77, Jan 1994. URL: https://doi.org/10.3109/15513819409022027, doi:10.3109/15513819409022027. This article has 33 citations.

  8. (bakula2014giantcellhepatitis pages 1-3): Agnieszka Bakula, Piotr Socha, Maja Klaudel‐Dreszler, Grazyna Karolczyk, Malgorzata Wozniak, Olga Rutynowska‐Pronicka, and Michal Matysiak. Giant cell hepatitis with autoimmune hemolytic anemia in children: proposal for therapeutic approach. Journal of Pediatric Gastroenterology and Nutrition, 58:669–673, May 2014. URL: https://doi.org/10.1097/mpg.0000000000000270, doi:10.1097/mpg.0000000000000270. This article has 33 citations and is from a peer-reviewed journal.

  9. (paganelli2014anticd20treatmentof pages 1-2): Massimiliano Paganelli, Natacha Patey, Lee M. Bass, and Fernando Alvarez. Anti-cd20 treatment of giant cell hepatitis with autoimmune hemolytic anemia. Pediatrics, 134:e1206-e1210, Oct 2014. URL: https://doi.org/10.1542/peds.2014-0032, doi:10.1542/peds.2014-0032. This article has 23 citations and is from a highest quality peer-reviewed journal.

  10. (whitington2014humoralimmunemechanism pages 1-1): Peter F. Whitington, Miriam B. Vos, Lee M. Bass, Hector Melin‐Aldana, Rene Romero, Claude C. Roy, and Fernando Alvarez. Humoral immune mechanism of liver injury in giant cell hepatitis with autoimmune hemolytic anemia. Journal of Pediatric Gastroenterology and Nutrition, 58:74–80, Jan 2014. URL: https://doi.org/10.1097/mpg.0b013e3182a98dbe, doi:10.1097/mpg.0b013e3182a98dbe. This article has 39 citations and is from a peer-reviewed journal.

  11. (marsalli2016efficacyofintravenous pages 4-5): Giulia Marsalli, Silvia Nastasio, Marco Sciveres, Pier Luigi Calvo, Ugo Ramenghi, Simona Gatti, Veronica Albano, Sara Lega, Alessandro Ventura, and Giuseppe Maggiore. Efficacy of intravenous immunoglobulin therapy in giant cell hepatitis with autoimmune hemolytic anemia: a multicenter study. Clinics and research in hepatology and gastroenterology, 40 1:83-9, Feb 2016. URL: https://doi.org/10.1016/j.clinre.2015.03.009, doi:10.1016/j.clinre.2015.03.009. This article has 24 citations and is from a peer-reviewed journal.

  12. (marsalli2016efficacyofintravenous pages 6-7): Giulia Marsalli, Silvia Nastasio, Marco Sciveres, Pier Luigi Calvo, Ugo Ramenghi, Simona Gatti, Veronica Albano, Sara Lega, Alessandro Ventura, and Giuseppe Maggiore. Efficacy of intravenous immunoglobulin therapy in giant cell hepatitis with autoimmune hemolytic anemia: a multicenter study. Clinics and research in hepatology and gastroenterology, 40 1:83-9, Feb 2016. URL: https://doi.org/10.1016/j.clinre.2015.03.009, doi:10.1016/j.clinre.2015.03.009. This article has 24 citations and is from a peer-reviewed journal.

  13. (kim2020successfultreatmentof pages 5-6): Young Ho Kim, Ju Whi Kim, Eun Joo Lee, Gyeong Hoon Kang, Hyoung Jin Kang, Jin Soo Moon, and Jae Sung Ko. Successful treatment of a korean infant with giant cell hepatitis with autoimmune hemolytic anemia using rituximab. Pediatric Gastroenterology, Hepatology & Nutrition, 23:180-187, Mar 2020. URL: https://doi.org/10.5223/pghn.2020.23.2.180, doi:10.5223/pghn.2020.23.2.180. This article has 9 citations and is from a peer-reviewed journal.

  14. (marsalli2016efficacyofintravenous pages 2-3): Giulia Marsalli, Silvia Nastasio, Marco Sciveres, Pier Luigi Calvo, Ugo Ramenghi, Simona Gatti, Veronica Albano, Sara Lega, Alessandro Ventura, and Giuseppe Maggiore. Efficacy of intravenous immunoglobulin therapy in giant cell hepatitis with autoimmune hemolytic anemia: a multicenter study. Clinics and research in hepatology and gastroenterology, 40 1:83-9, Feb 2016. URL: https://doi.org/10.1016/j.clinre.2015.03.009, doi:10.1016/j.clinre.2015.03.009. This article has 24 citations and is from a peer-reviewed journal.

  15. (whitington2014humoralimmunemechanism pages 3-6): Peter F. Whitington, Miriam B. Vos, Lee M. Bass, Hector Melin‐Aldana, Rene Romero, Claude C. Roy, and Fernando Alvarez. Humoral immune mechanism of liver injury in giant cell hepatitis with autoimmune hemolytic anemia. Journal of Pediatric Gastroenterology and Nutrition, 58:74–80, Jan 2014. URL: https://doi.org/10.1097/mpg.0b013e3182a98dbe, doi:10.1097/mpg.0b013e3182a98dbe. This article has 39 citations and is from a peer-reviewed journal.

  16. (whitington2014humoralimmunemechanism pages 6-6): Peter F. Whitington, Miriam B. Vos, Lee M. Bass, Hector Melin‐Aldana, Rene Romero, Claude C. Roy, and Fernando Alvarez. Humoral immune mechanism of liver injury in giant cell hepatitis with autoimmune hemolytic anemia. Journal of Pediatric Gastroenterology and Nutrition, 58:74–80, Jan 2014. URL: https://doi.org/10.1097/mpg.0b013e3182a98dbe, doi:10.1097/mpg.0b013e3182a98dbe. This article has 39 citations and is from a peer-reviewed journal.

  17. (whitington2014humoralimmunemechanism pages 1-2): Peter F. Whitington, Miriam B. Vos, Lee M. Bass, Hector Melin‐Aldana, Rene Romero, Claude C. Roy, and Fernando Alvarez. Humoral immune mechanism of liver injury in giant cell hepatitis with autoimmune hemolytic anemia. Journal of Pediatric Gastroenterology and Nutrition, 58:74–80, Jan 2014. URL: https://doi.org/10.1097/mpg.0b013e3182a98dbe, doi:10.1097/mpg.0b013e3182a98dbe. This article has 39 citations and is from a peer-reviewed journal.